Skip to main content

Pharmacology's Krzysztof Palczewski provides key discovery for new therapy for patients with retinal degeneration diseases

Boston biopharmaceutical company licenses technology from Case Western Reserve University Crain’s Cleveland Business: Case Western Reserve University reached a licensing agreement with Vision Medicines Inc., a Boston-based clinical-stage biopharmaceutical company developing therapies for patients suffering from retinal degeneration diseases. Krzysztof Palczewski, the John H. Hord Professor and chair of the Department of Pharmacology, made a key discovery that led to the therapy’s creation.
EXPLORE MORE:
Media